Bionano Genomics presented optical genome mapping alongside an estimated global total addressable market approaching $10B. The presentation also cited unique CPT codes, routine-use customers accounting for 83% of consumables revenue, and a focus on 25% of customers representing 75% of sales, giving investors specific markers for adoption and commercial concentration.
Key Highlights
- Optical genome mapping was linked to clinical applications in hematologic oncology and constitutional genetic disease.
- Routine-use customers represented 83% of FY25 consumables revenue, with average Revenue per site of $89K.
- Two unique CPT codes have been established for optical genome mapping analysis in hematologic malignancies and constitutional genetics.
Bionano Genomics, Inc. (NASDAQ: BNGO) presented optical genome mapping alongside an estimated global total addressable market approaching $10B.
OGM Moves Further Into Clinical Use
The presentation described optical genome mapping as moving into clinical practice for structural-variant analysis, with clinical publications highlighting potential use in hematologic oncology and constitutional genetic diseases. The materials also identified applications in cell and gene therapy quality control. Unique CPT codes have been established for OGM analysis in hematologic malignancies and constitutional genetics. A public comment period was recently announced for a Medicare coverage proposal involving OGM-based detection of copy number alterations and structural variants in hematologic neoplasms. The presentation positioned Bionano’s Stratys system and VIA software as tools intended to increase throughput and simplify OGM data analysis. It also described OGM as addressing gaps left by traditional cytogenetic methods and sequencing approaches.
Customer Mix Drives Commercial Focus
Routine-use customers were shown at approximately 130 customers, representing 40% of sites and 83% of FY25 consumables revenue, with average revenue per site of $89K. A group of approximately 60 customers represented 56% of consumables revenue and $131K in average revenue per site, while approximately 55 customers represented 19% and $48K per site. The strategy de-emphasized instrument sales, prioritized flowcell utilization and routine use, and eliminated nonessential Business activities. The company said discontinuing its legacy Lineagen business while retaining its CLIA-certified laboratory resulted in a negative $7 MM top-line revenue impact.




Please wait processing your request...